Akums Drugs & Pharmaceuticals, India’s largest contract development and manufacturing organization (CDMO), has secured a significant agreement with a leading global pharmaceutical company to manufacture and supply oral liquid formulations for the European market. This deal, valued at approximately €200 million (INR 1,760 crores), involves multiple product lines to be marketed in several European countries.
Akums will commence product supply in 2027, with the contract extending until 2032. The company will receive an upfront payment of €100 million for product development and obtaining necessary approvals from European authorities. This agreement follows Akums’ recent acquisition of the European Union Good Manufacturing Practice (EU GMP) approval for two of its manufacturing facilities in Haridwar, India, which allows them to produce and export pharmaceuticals to Europe.
Key Insights:
- Expansion into Regulated Markets: This deal marks a strategic move by Akums to expand its presence in the highly regulated European pharmaceutical market. It leverages the company’s existing EU GMP certifications and demonstrates its capability to meet international quality standards.
- CDMO Sector Growth: The agreement highlights the growth potential of the CDMO sector in India, particularly in the export market. Akums’ success could encourage other Indian pharmaceutical companies to explore similar opportunities.
- Financial Boost: The €200 million deal and the substantial upfront payment provide a significant financial boost to Akums, strengthening its position for future growth and investment.
Investment Implications:
- Positive Sentiment for Akums: This news is likely to generate positive sentiment around Akums Drugs & Pharmaceuticals. Investors may view this deal as a sign of the company’s strong growth prospects and its ability to compete in the global market.
- Potential for Increased Revenue and Profitability: The long-term supply contract could significantly contribute to Akums’ revenue and profitability in the coming years.
- Boost for the Indian Pharmaceutical Industry: The deal reinforces the reputation of the Indian pharmaceutical industry in the global market, potentially attracting further investment and partnerships.
Sources:
